Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 5,826

Document Document Title
WO/2008/101313
The present invention describes compounds produced from an amino acid molecule and a fatty acid molecule. The compounds being in the form of amino-fatty acid compounds being bound by an amide linkage, or mixtures thereof made by reacting...  
WO/2008/101824
The present invention relates to a compound of the formula (I) in which: R1 is a hydrogen atom or a C1- C6 alkoxy group; R2 is a hydrogen atom or a C1- C6 alkyl group optionally substituted by a hydroxy group; R3 is a hydrogen atom, a C1...  
WO/2008/096769
PPARγ activators/modulators which contain as the active ingredient cercosporamide derivatives represented by the general formula (I) or pharmacologically acceptable salts or esters thereof; and pharmaceutical compositions for the treatm...  
WO/2008/095356
Methods for treating SMA in a subject comprise administering to the subject a recombinant genetic vector comprising at least one copy of a Stathmin inhibitor. The inhibitor can be a Stathmin expression inhibitor. The inhibitor can be or ...  
WO/2008/096755
Disclosed is a novel vanilloid receptor (VR1) inhibitor which can be used as an effective therapeutic agent for an acute pain and/or a chronic pain which has less adverse side effects and can be used safely. The vanilloid receptor (VR1) ...  
WO/2008/095357
Compositions for treatment of spinal muscular atrophy (SMA) and methods for use thereof to treat SMA and other conditions of SMN-deficiency; novel drug development targets for SMA therapies, and methods of use thereof to screen for candi...  
WO/2008/090940
Disclosed are: a pharmaceutical agent which is effective on a disease induced by the over-response of Th2 or Th17 (e.g., multiple sclerosis); and a method for efficient screening of the pharmaceutical agent. Specifically disclosed are: a...  
WO/2008/090944
Disclosed is a compound represented by the formula (I) or a salt thereof, which has an inhibitory activity on acetyl-CoA carboxylase (ACC), is therefore useful for the prevention/treatment of obesity, diabetes, hypertension, hyperlipemia...  
WO/2008/087705
It is intended to provide a composition for inhibiting muscle damage which has high safety and a more potent effect on inhibiting muscle damage. The invention provides the composition for inhibiting muscle damage characterized by contain...  
WO/2008/084368  
WO/2008/084368  
WO/2008/084368  
WO/2008/081989
Disclosed is a nerve regeneration agent which contains, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a component fatty acid.  
WO/2008/078411
Disclosed is a pharmaceutical agent for the prevention and/or treatment of an inflammatory myopathy, which comprises a retinoid such as 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalenyl)carbamoyl]benzoic acid as an active ingred...  
WO/2008/077170
The invention relates to the use of a compound of general formula (I), wherein Y is selected from among the group comprising thienyl, pyridyl, and formula (a), wherein each radical R represents hydrogen or a substituent selected from amo...  
WO/2008/078715
It is intended to provide an excellent therapeutic agent for inflammatory myopathy which can significantly suppress symptoms of inflammatory myopathy such as abnormal inflammatory cell infiltration in muscle fibers and does not have disa...  
WO/2008/077170
The invention relates to the use of a compound of general formula (I), wherein Y is selected from among the group comprising thienyl, pyridyl, and formula (a), wherein each radical R represents hydrogen or a substituent selected from amo...  
WO/2008/075206
A method has been developed to produce stable cell-matrix microspheres with up to 100% encapsulation efficiency and high cell viability, using matrix or biomaterial systems with poor shape and mechanical stability for applications includ...  
WO/2008/073351
The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.  
WO/2008/072663
Disclosed is a composition for ameliorating/preventing an adverse side effect which may occur in steroid therapy or a composition for suppressing a muscular-atrophy-related gene, which comprises isoleucine, leucine and valine as active i...  
WO/2008/073466
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, p...  
WO/2008/067863
The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6...  
WO/2008/067863
The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6...  
WO/2008/066117
Disclosed is a compound having excellent androgen receptor modulating activity. Specifically disclosed is a compound represented by the formula (I) or a salt thereof. (I) wherein R1, R2 and R4 to R6 independently represent a hydrogen ato...  
WO/2008/067480
The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy ...  
WO/2008/066145
Disclosed are: a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a VAP-1 inhibitor; a pharmaceutical composition; a pharmaceutical agent for the prevention or treatment of a VAP-1...  
WO/2008/067527
The invention relates to the use of protein tyrosine phosphatase inhibitors for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2008/067480
The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy ...  
WO/2008/059959
It is intended to contribute to the elucidation of the mechanism of postzoster neuralgia and to provide means for promoting the regeneration of damaged nerve. Further, it is intended to provide means which is effective in the prevention ...  
WO/2008/060051
Disclosed herein is a transnasal anticonvulsive pharmaceutical composition comprising diazepam as an active ingredient, water, a fatty acid ester, diethylene glycol monoethyl ether, ethanol and sodium glycocholate, wherein the weight of ...  
WO/2008/056452
[PROBLEMS] To provide a drug or a food for specified health uses aiming at slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis. [MEANS FOR SOLVING PROBLEMS] An agent containing D-allose as the a...  
WO/2008/054188
The invention relates to pharmaceutical compositions containing a muscle relaxant known as carisoprodol and a non-steroidal antiinflammatory analgesic known as lysine clonixinate. When the aforementioned drugs are combined in specific pr...  
WO/2008/053362
The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by p...  
WO/2008/050732
Disclosed are: an iminopyridine derivative which has a selective antagonistic activity on an α1D adrenergic receptor and is useful as a prophylactic/therapeutic agent for lower urinary tract disease or the like; and a method for the scr...  
WO/2008/050866
It is intended to provide a novel botulinum toxin type A preparation. An inhibitor of neuromuscular transmission containing a highly purified botulinum toxin type A derived from Clostridium botulinum causing infant botulism as an active ...  
WO/2008/051795
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/051795
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/047821
Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity or the like. Specifically disclosed is a glucokinase activator comprising a compound represente...  
WO/2008/048689
The use of therapeutics capable of inhibiting complement such as an anti-C5 antibody to treat muscular dystrophy associated with dysferlin-deficiency is disclosed.  
WO/2008/047241
The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically υrocortin and υrocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides an...  
WO/2008/044656
Disclosed is an imidazolidinone derivative represented by the formula (1), a pharmaceutically acceptable salt thereof, or a hydrate of the derivative or the salt, which has a satisfactory therapeutic effect that relies on a 11β-HSD1-inh...  
WO/2008/044785
Disclosed is a material for improving the cerebral blood flow, which comprises a plant-derived carbon fiber. The material produces no adverse side-effect and is therefore safe, and can improve the cerebral blood flow effectively. Also di...  
WO/2008/041236
Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consi...  
WO/2008/041751
Fibromyalgia is a disease for which development of a therapeutic agent is difficult to achieve because the cause or mechanism of onset thereof has not been elucidated yet. When salazosulfapyridine, which is a therapeutic agent for rheuma...  
WO/2008/041236
Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consi...  
WO/2008/040550
Olive extracts comprising hydroxytyrosol are effective in promoting muscle health in both animals and humans which are subject to muscle damage, muscle pain and muscle soreness due to exercise. The olive extracts can decrease the accumul...  
WO/2008/040550
Olive extracts comprising hydroxytyrosol are effective in promoting muscle health in both animals and humans which are subject to muscle damage, muscle pain and muscle soreness due to exercise. The olive extracts can decrease the accumul...  
WO/2008/038644
[PROBLEMS] To provide a novel pharmaceutical agent having an excellent prophylactic effect on RSD developed after stroke. [MEANS FOR SOLVING PROBLEMS] An agent for preventing the development of RSD after stroke, comprising naturally occu...  
WO/2008/037258
[2-(6-fluoro-lH-indol-3-ylsulfanyl)benzyl]methyl amine and pharmaceutically acceptable salts thereof, provided it is not the free base in a non-crystalline form are provided for the treatment of affective disorders.  
WO/2008/039085
The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.  

Matches 701 - 750 out of 5,826